Zhitong Financial App News, New Open Source (300109.SZ) announcement, the company shares in Yongtai Biopharmaceutical Co., Ltd. (referred to as "Yongtai Biology", 1.4%) its core product-expanded activated lymphocytes (EAL))-indications for preventing recurrence after radical resection of primary hepatocellular carcinoma have been incorporated into a breakthrough treatment by the Drug Evaluation Center of the State Drug Administration (CDE).
It is reported that as the first domestic cell therapy product approved to be used in clinical trials to prevent postoperative recurrence of liver cancer, EALOnce approved, it will change the current situation that there is no effective treatment for postoperative recurrence of liver cancer, and it will also become the first solid tumor cell therapy product on the market in China. As of the announcement date, Yongtai has completed 430 target patients in the phase II clinical trial and will submit a new drug application for the product to the State Drug Administration in 2023, and the product is expected to be on the market in 2024.